dobutamine has been researched along with ibopamine in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (44.44) | 18.7374 |
1990's | 4 (44.44) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Erhardt, PW | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Costa, R; De Marino, V; Marino, A | 1 |
van Zwieten, PA | 1 |
Carey, RA; Jacob, L | 1 |
Goldberg, LI; Rajfer, SI | 2 |
Lie, KI; van Zwieten, PA | 1 |
Campa, PP; Dawodu, AA; De Biase, L; Gentile, C; Lilla Della Monica, PL; Monti, F; Puddu, PE; Schiariti, M; Vaccaro, M | 1 |
4 review(s) available for dobutamine and ibopamine
Article | Year |
---|---|
In search of the digitalis replacement.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Heart Failure; Humans; Myocardial Contraction; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1987 |
[Physiological bases and therapeutic uses of inodilator drugs].
Topics: Amrinone; Cardiotonic Agents; Deoxyepinephrine; Dobutamine; Dopamine; Heart Failure; Humans; Milrinone; Phosphodiesterase Inhibitors; Pyridones; Sympathomimetics; Vasodilator Agents | 1991 |
The role of dopaminergic agents and the dopamine receptor in treatment for CHF.
Topics: Benzazepines; Deoxyepinephrine; Dobutamine; Dopamine; Dopamine Agents; Fenoldopam; Heart Failure; Humans; Levodopa; Receptors, Dopamine | 1989 |
[Neurohormonal compensation processes in chronic heart failure: the effect of drugs].
Topics: Adrenergic beta-Agonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiac Glycosides; Cardiotonic Agents; Deoxyepinephrine; Diuretics; Dobutamine; Heart Failure; Humans; Receptors, Cell Surface; Renin-Angiotensin System; Sympathetic Nervous System | 1994 |
5 other study(ies) available for dobutamine and ibopamine
Article | Year |
---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
[Dopamine and dopaminergic drugs as therapeutic agents in heart failure].
Topics: Deoxyepinephrine; Dobutamine; Dopamine; Dopamine Agents; Heart Failure; Hemodynamics; Humans; Vasodilator Agents | 1990 |
The role of adrenergic and dopamine receptors.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiotonic Agents; Deoxyepinephrine; Dobutamine; Dopamine; Heart Failure; Hemodynamics; Humans; Levodopa; Receptors, Adrenergic; Receptors, Dopamine | 1985 |
Sympathomimetic amines: potential clinical applications in ischemic heart disease.
Topics: Animals; Coronary Disease; Deoxyepinephrine; Dobutamine; Dogs; Dopamine; Heart Failure; Humans; Levodopa; Myocardial Contraction; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Receptors, Dopamine; Sympathomimetics | 1982 |
[Refractory heart failure: it requires the use of polychemotherapy. What is the rationale?].
Topics: Adrenergic Agonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilated; Cyclooxygenase Inhibitors; Deoxyepinephrine; Digitalis Glycosides; Diuretics; Dobutamine; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Heart Failure; Humans; Nitrates; Phosphodiesterase Inhibitors; Vasodilator Agents | 1995 |